Sauce Labs Launches Industry-First Enterprise Scale iOS 18 Testing on Sauce Labs Virtual Device Cloud, Boosting Test Speeds up to 40%
24.4.2025 08:00:00 CEST | ACCESS Newswire | Press release
Leading test automation platform, powering development for over 300,000 active users and having executed more than 8 billion tests, enables developers and QA teams to ensure app quality on Apple's latest OS with unprecedented performance and scale.
SAN FRANCISCO, CA / ACCESS Newswire / April 24, 2025 / Sauce Labs Inc., the leading platform for continuous quality, trusted by dev teams around the world to deliver apps users love, today announced the general availability of iOS 18 testing on its Virtual Device Cloud (VDC). Leveraging its new, high-performance Apple Silicon cloud infrastructure, Sauce Labs offers the market's most scalable enterprise-ready solution for automated mobile app and web testing on iOS 17.5, iOS 18, and beyond, enabling teams to execute tests up to 40% faster compared to previous versions.
This launch addresses the critical need for timely testing support driven by Apple's transition to its proprietary Apple Silicon architecture and the rapid adoption rate of new iOS versions. Within just four months of its release, iOS 18 was reportedly installed on nearly 70% of devices connecting to the App Store, making immediate testing capabilities essential for businesses to maintain quality user experiences.
Sauce Labs' enhanced VDC, now with iOS 18 support, delivers significant performance improvements. Benchmark tests show up to 65% faster session start times and up to 40% faster test execution speeds for iOS 18 simulations compared to earlier versions.
"Staying ahead in the mobile landscape means testing where your users are - and Apple users adopt new operating systems faster than anyone," said Shubha Govil, Chief Product Officer of Sauce Labs. "We are committed to providing the latest to empower developers and QA teams, and our investment to support scalable iOS 18 testing underscores that. Developers can now confidently build and release high-quality apps that leverage the latest iOS features, ensuring seamless user experiences from day one, with significant gains in testing speed and efficiency, all backed by the robust platform trusted by hundreds of thousands of developers globally."
With Sauce Labs' support for iOS 17.5 and iOS 18 simulators, development and QA teams can:
Mitigate Risks Early: Achieve comprehensive test coverage for the latest Apple operating systems, identifying and fixing bugs earlier in the development cycle.
Improve Performance: Experience significantly faster test execution (up to 40%) and session start times (up to 65%) on the optimized iOS 18 simulators in VDC.
Ensure Compatibility: Test against new iOS 18 features like enhanced Siri capabilities, Apple Intelligence frameworks, and Swift 6 advancements.
Build User Trust: Deliver smooth, reliable app performance with each iOS update, preventing compatibility issues and crashes.
Test with Proven Scale: Leverage the industry's most scalable cloud solution - offering access to over 9,000 real devices and 2,500+ emulators/simulators & browser/OS combinations, and proven with over 8 billion tests executed - for iOS 18 automated testing for both iPhone and iPad models.
Leading global organizations participating in the Sauce Labs beta program are already experiencing the advantages. "The team was running tests on iOS 17 but our train conductors use devices running iOS 18," stated Bruno Quercia, Product Manager at SNCF Connect & Tech. "Moving to iOS 18 on Sauce Labs simulators let us exactly mimic these devices for quality testing, plus our test durations have reduced by 4X."
Sauce Labs continues to invest in its unified platform, ensuring development teams have the coverage, speed, and insights needed to release quality software with confidence.
Sauce Labs' iOS 18 support is available now for automated mobile app and web testing via the Sauce Labs Virtual Device Cloud.
To learn more about testing on iOS 18 with Sauce Labs and its performance advantages, visit https://saucelabs.com/. Detailed documentation is available here.
About Sauce Labs
Sauce Labs is the leading platform for continuous quality, trusted by the world's top enterprises - like Walmart, Bank of America, and Indeed. Over 300,000 users depend on Sauce Labs to help them quickly deliver the highest quality software experiences. Our unified platform powers continuous quality across the SDLC - using AI-driven analytics to identify key quality signals from development through production. With over a decade of expertise and deep roots in the Selenium and Appium open-source communities, Sauce Labs helps teams test on thousands of different devices, browsers, and operating systems - anywhere, any time, and at any scale. For more information, please visit saucelabs.com.
Media Contact:
Justin Mauldin
Salient PR
achievemore@salientpr.com
737.234.0936
###
SOURCE: Sauce Labs
View the original press release on ACCESS Newswire
Sauce Labs

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
RE Royalties Announces Second Tranche Investment of $800,000 in Solaris Energy's U.S. Distributed Generation Solar Portfolio9.2.2026 23:00:00 CET | Press release
All amounts in US dollars unless otherwise stated. VANCOUVER, BC / ACCESS Newswire / February 9, 2026 / RE Royalties Ltd. (TSX.V:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce a further USD $800,000 investment toward the purchase of royalties on two portfolios of distributed generation ("DG") solar projects located throughout the United States being developed by Solaris Energy Inc. ("Solaris"). The Royalty Purchase for Portfolio 1 totals USD $4.8 million, of which USD $3 million was funded at closing, as announced on January 7, 2026. The Company expects to fund the remaining USD $1 million by Q2 2026, subject to the satisfaction of applicable conditions. The Royalty Purchase for Portfolio 2 is subject to the completion of due diligence to the satisfaction of the Company, other customary closing conditions, and is expected to occur later in the year, bringing the total portfolio level royalty investment to USD $9 million. The Royalty Rate will be adju
UK-Based Vesalic Limited Emerges from Stealth with Landmark Discovery of Potential Non-CNS Driver of Motor Neuron Diseases, including ALS, and Breakthrough Therapeutic and Diagnostic Opportunities9.2.2026 06:00:00 CET | Press release
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo in ALS patients, which is carried to the CNS, where it binds to and damages neurons Vesalic is pioneering a novel therapeutic to intercept and neutralise these toxins, potentially slowing or halting progression of monogenic and sporadic forms of ALS In addition, Vesalic has discovered a disease-specific alteration of the lipid composition in the membranes of exosomes circulating in the blood, and has developed a highly accurate biomarker-based technology to detect both monogenic and sporadic ALS Based on its novel biomarker discoveries, Vesalic is also applying its biomarker technology for other neurodegenerative diseases, including Alzheimer's and Parkinson's LONDON, UK / ACCESS Newswire / February 9, 2026 / Vesalic Limited, an early-stage neurodegenerative disease-focused biotech company, today emerged from stealth with the landmark discovery of a systemic process - largely
Innodata to Report Fourth Quarter and Fiscal Year 2025 Results5.2.2026 14:30:00 CET | Press release
NEW YORK, NY / ACCESS Newswire / February 5, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Fourth Quarter and Fiscal Year 2025 results after the market closes on Thursday, February 26, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+44) 800 279 7040 United Kingdom (+1) 289 819 1520 International Participant Access Code 27117 # Replay dial-In (+1) 888 660 6264 North America (+1) 289 819 1325 International: Replay Passcode 27117 # Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be av
Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release
Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom